TMS Icon
Clinical trial updates

INTERCEPT™(pathogen inactivation)

Less than a minute
  • Product Information

    Product Information

    Scientific name: Pathogen Inactivation
    Brand name: INTERCEPT™ Blood System
    RESPONSIBLE: Cerus Corporation

  • Clinical Trial/Study Information

    Clinical Trial/Study Information

    Trial Name: N/A – INTERCEPT™ is a medical device not a drug/medicinal product.
    Code: N/A (
    Phase: Ν/Α
    Eligible patient diagnosis: Ν/Α
    No. of Patients enrolled: N/A
    Study Sites: N/A Sites per country

    Anticipated completion date: Ν/Α
    Scope of the Study / Aim: Ν/Α

  • Regulatory Information

    Regulatory Information

    Status: Authorised

    Additional notable points:

    • EMA: CE approved for plasma (2006), platelets (2002) (medical device)
    • FDA: Approved for plasma (2020), platelets (2014)
    • MHRA: N/A

Update: 19 December 2024

No update available.

 

Update: 30 September 2024

No update available.

 

Update: 30 June 2024

No update available.

 

Update: 31 March 2024

No update available.

 

Update: 20 December 2023

No update available.

 

Update: 30 September 2023

No update available.


Update: 30 June 2023

Sessions at the Annual ISBT Congress (Gothenberg, Sweden) held on 17-21 June 2023, highlighted that the experience of pathogen-reduced plasma and platelets has shown to significantly and cost-effectively reduce transfusion-transmitted infections and called for increased data for the efficacy in RBCs which are the most commonly used blood component in Europe.

Source: Parallel Session 8: Pathogen inactivation PA08-L01
https://onlinelibrary.wiley.com/doi/10.1111/vox.13433


Update: 31 March 2023

No update available.

Less than a minute
Back to top button